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Abstract 
Background: The equine infectious anemia virus (EIAV) vaccine is the only attenuated lentiviral vaccine applied on a 
large scale that has been shown to be effective in controlling the prevalence of EIA in China. This vaccine was devel‑
oped by successive passaging of a field‑isolated virulent strain in different hosts and cultivated cells. To explore the 
molecular basis for the phenotype alteration of this vaccine strain, we systematically analyzed its genomic evolution 
during vaccine development.
Results: Sequence analysis revealed that the genetic distance between the wild‑type strain and six representative 
strains isolated from key development stages gradually increased with the number of passages. Env gene, but not gag 
and pol, showed a clear evolutionary flow similar to that of the whole genomes of different generations during the 
attenuation. Stable mutations were identified in multiple regions of multiple genes along with virus passaging. The 
adaption of the virus to the growth environment of cultured cells with accumulated genomic and genetic variations 
was positively correlated with the reduction in pathogenicity and rise of immunogenicity. Statistical analyses revealed 
significant differences in the frequency of the most stable mutations between in vivo and ex vivo‑adapted strains and 
between virulent and attenuated strains.
Conclusions: These data indicate that EIAV evolution during vaccine development generated an accumulation of 
mutations under the selective drive force, which helps to better understand the molecular basis of lentivirus patho‑
genicity and immunogenicity.
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Background
Vaccination is the most effective means of controlling 
infectious diseases. However, the development of a safe 
and effective lentiviral vaccine, such as a human immu-
nodeficiency virus-1 (HIV-1) vaccine, remains a huge 
scientific challenge. Studies on the development of lenti-
viral vaccines targeting HIV-1, simian immunodeficiency 
virus (SIV), chimeric simian-human immunodeficiency 
virus (SHIV), equine infectious anemia virus (EIAV) and 
feline immunodeficiency virus (FIV) have demonstrated 
that the live attenuated formulation is the most effective 
formulation [1, 2]. Because lentiviral genomes integrate 
into host chromosomes and feature a high frequency of 
genomic mutations, attenuated live vaccines are generally 
not considered as an option for practical lentiviral vac-
cines. However, the study of immune responses induced 
by attenuated vaccines can provide a useful reference to 
elucidate the protective immune responses to lentiviral 
infections [3].
EIAV is a member of the Lentivius genus in the Retro-
viridae family. The major features of EIAV, including its 
genomic structure, life cycle, in  vivo antigen evolution, 
cell tropism and the interaction between the virus and 
host, are similar to HIV-1. Most horses infected with 
EIAV exhibit a repeated high-titer viremia with typical 
clinical features such as fever, thrombocytopenia and 
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anemia. Some infected horses may eventually control 
viral replication and become asymptomatic carriers after 
several months or years of acute or chronic infection. 
EIAV infection is life-long.
EIAVLN40, which is an EIAV strain that is highly lethal 
to horses (experimental lethality of 80–100 %), was devel-
oped by passaging a field isolate in horses for 16 passages. 
The pathogenicity of this virus in donkeys was largely 
enhanced (raised from generally asymptomatic to near 
100 % lethality) by the continuous passaging of EIAVLN40 
in donkeys for 117 rounds (Fig. 1a). The resultant strain 
(EIAVDV117) was subsequently continuously acclimatized 
in cultivated primary donkey monocyte-derived mac-
rophages (dMDM). The lethality of EIAVDV117 to horses 
and donkeys was gradually decreased by passaging in 
dMDM and was finally reduced to the point of not caus-
ing any clinical symptoms in either horses or donkeys 
after 90 passages (Fig.  1b). The ability to induce pro-
tective immunity in inoculated horses was detected in 
viruses that were attenuated in dMDM for approximately 
110–125 passages. The resultant viral strain (termed EIA-
VDLV121) was able to elicit resistance to challenge with 
EIAVLN40 (the average genomic divergence to EIAVDLV121 
was 2.8 %) in >75 % of the inoculated horses and >95 % 
of the inoculated donkeys. This attenuated viral strain 
was used as a vaccine to massively immunize 61 mil-
lion horses and mules to prevent EIA infection in China 
from 1975 to the 1990s [4]. This nationwide vaccination 
program ended the incidence of equine infectious ane-
mia (EIA) in this country. The successful application of 
the EIAV vaccine has provided an important and unique 
reference model for studies on lentivirus immunity and 
vaccines. EIAVDLV121 was further adapted to cultivated 
fetal donkey dermal (FDD) cells (termed EIAVFDDV13) 
to reduce the preparation costs of this attenuated EIAV 
strain. Part of the historic data on EIAVDLV121 protection 
of disease in laboratory infected horses indicated that the 
protection efficiency to challenge with the parental viru-
lent strain (EIAVLN40, the average variation in Env amino 
acid sequences is 7.1 %) and an American strain (EIAVW-
yoming, the average variation in Env amino acid sequences 
is 37.8 %) was 81 % (25/31) and 80 % (8/10), respectively 
[4]. Our resent experiments on the immunogenicity of 
EIAVDLV121 and EIAVFDDV13 demonstrated a 50  % (2/4) 
and 83 % (5/6) similar protection of disease (Additional 
file 1: Table S1) [4, 5].
During the development process of the attenuated 
EIAV vaccine, a series of virus strains with different 
pathogenicities or immunogenicities were obtained. 
These strains provided a useful resource for the study 
of essential factors that induce protective immunity 
to lentiviruses. In this article, we analyzed the provi-
ral genomic characteristics and the evolutionary trend 
of representative strains from key stages of the process, 
including EIAVLN40, EIAVDV117, EIAVDLV34, EIAVDLV62, 
EIAVDLV92, EIAVDLV121 and EIAVFDDV13. Among these 
strains, EIAVDLV34, EIAVDLV62 and EIAVDLV92 were col-
lected from the 34th, 62nd and 92nd passages of EIA-
VDV117 in dMDM, respectively (Fig. 1a).
Results and discussion
Analysis of viral genome variants over the course of the 
development of an attenuated EIAV vaccine
To examine the overall contributions of genes or gene 
fragments of the EIAV genome to the evolution of this 
virus during the development of the vaccine strains EIA-
VDLV121 and EIAVFDDV13, the frequency of each nucleotide 
of 65 full genomic sequences of EIAV strains sampled 
from key stages of the process was analyzed using Shan-
non Entropy (SE). As presented in Fig.  1c, nucleotides 
with high SE values were not randomly distributed but 
were clustered as different-sized islands. These nucleo-
tides were largely located in the LTR and env regions.
The proviral genome size of different EIAV strains 
ranged from 7549 to 8277 bp. A detailed analysis of the 
average mutation rates of different genes and the LTR 
revealed that the overall diversity among the total 65 
genomes of the seven EIAV strains was 2.0 %. The diver-
sity was highest in the LTR (2.95 ± 0.26 %), followed by 
env (consisting of the gp90 and gp45 genes, which were 
2.90  ±  0.19 and 2.11  ±  0.26  %, respectively) (Fig.  1d). 
The variation in the encoded proteins among these EIAV 
strains was considerably higher. The S2 accessary pro-
tein exhibited the highest diversity in the amino acid 
sequence, reaching 5.02 ± 1.58 %, followed by the surface 
unit (SU or gp90) of the envelope protein (Env) and Rev, 
which were 4.81 ± 0.48 and 3.99 ± 0.84 %, respectively 
(Fig.  1d). Moreover, the genetic distances between the 
different viral strains and the parental strains EIAVLN40 
and EIAVDV117 gradually increased with the increasing 
passage numbers (Table 1).
Phylogenetic analysis of strains collected during the 
development of an attenuated EIAV vaccine
Phylogenetic trees were constructed based on the 65 
full-length proviral genomic sequences (Fig. 2). The clus-
ters of each individual genome clearly demonstrated the 
evolutionary direction from EIAVLN40 to EIAVFDDV13. 
Changes in the viral growth environment inevitably cre-
ated new branches in the phylogenetic tree [i.e., chang-
ing the host from horse to donkey (between EIAVLN40 
and EIAVDV117) and shifting the cultivated cell type from 
dMDM to FDD (between EIAVDLV121 and EIAVFDDV13)]. 
Conversely, the evolution of EIAV was rather gradual and 
smooth under the same growth environment conditions, 
as shown by the overlap of the sequence distributions of 
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species from EIAVDLV34, EIAVDLV62 and EIAVDLV92 in the 
map. This result indicated that viral evolution was a long-
term process with selective mutations accumulating dur-
ing continuous passages in cultured cells. Furthermore, 
dramatic alterations of the growth environment could 
speed up viral genomic mutations.
The evolutionary behavior of each individual EIAV gene 
and the LTR region were also phylogenetically analyzed. 
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Fig. 1 Genome variants of EIAV strains during vaccine development. a The flowchart of EIAV vaccine development. Four major stages were 
included the process of vaccine development: the in vivo passages in horses and donkeys and the passages in cultured dMDM and fetal donkey 
dermal (FDD) cells. The representative strains isolated from each of these stages and the numbers of clones used for the proviral genome analysis 
are indicated. These viral strains included the virulent strains EIAVLN40 and EIAVDV117, the vaccine strains EIAVDLV121 and EIAVFDDV13 and three strains 
of EIAVDV117 passaged in dMDM (the 34th passage strain EIAVDLV34, the 62nd passage strain EIAVDLV62 and the 92nd passage strain EIAVDLV92). b The 
pathogenicity attenuation of EIAV strains during vaccine development. The percentages indicate the morbidity of horses or donkeys that were 
experimentally infected with the indicated viral strains. c Shannon entropy (SE) plots of EIAV complete genomic sequences depict the mutation fre‑
quency at each nucleotide position. Full genomic sequences of 65 clones from seven EIAV strains were isolated from different key stages of vaccine 
development. Refer to Fig. 1a for detailed information of these viral strains. Larger entropy values indicate higher mutation frequencies. The relative 
positions of EIAV individual genes are labeled. d The variations in the EIAV genome and individual genes and their encoded proteins among the 65 
clones from the seven representative strains. The diversities were calculated by computing the overall mean distances using the p‑distance method 
in MEGA 5 software
Page 4 of 13Wang et al. Retrovirology  (2016) 13:9 
Three different evolutionary patterns were observed, as 
presented in Fig. 2. The first pattern was observed for the 
env gene and clearly demonstrated a direction toward 
the flow of the vaccine development process similar to 
that identified for the total viral genome, with a remark-
able clustering of sequences from attenuated strains 
(EIAVDLV92, EIAVDLV121 and EIAVFDDV13) (Fig.  2). This 
result implied that there was a close association of the 
env evolution with the EIAV phenotypic change dur-
ing the in vivo and ex vivo passages. The pol sequences 
also displayed a separated distribution between the 
EIAV virulent and attenuated strains (Fig.  2). However, 
the genes were not well-separated among strains with a 
similar pathogenicity, suggesting a close association with 
pathogenicity. The second pattern was observed for LTR 
and gag (Fig.  2), which showed separated branches of 
sequences that clustered according to the different EIAV 
growth environments. Specifically, sequences of EIAVLN40 
(from horses), EIAVDV117 (from donkeys) and EIAVFDDV13 
(from FDD cells) each formed a clearly separated branch. 
Although clones from strains grown in eMDM (EIAVDLV 
strains 34, 62, 92 and 121) were well-distinguished from 
the other strains, sequences within these EIAVDLV strains 
were mixed in the sub-branches of their clusters. This 
phylogenetic pattern suggested the association of LTR 
and gag with EIAV adaption to the environmental change 
and the reduced importance of pathogenicity. The third 
genetic evolutionary pattern was observed for the genes 
of three accessory proteins (tat, s2 and rev) (Fig. 2). For 
tat and rev in particular, the sequence distribution in the 
phylogenetic tree did not follow the trend of in vivo and 
ex  vivo passaging of EIAV. Viral genes in different pas-
sages were largely mixed within different branches, dem-
onstrating no obvious evolutionary direction. However, 
s2 exhibited a separation between sequences from strains 
replicated either in vivo or cultured cells (Fig. 2).
Combined with Fig. 1d, which depicts the higher amino 
acid mutation rate, our data on EIAV genetic evolution 
suggest that: (1) Gag, Pol and accessary proteins have 
higher percentages of silent nt substitutions or substitu-
tions that are not consistent with the substitution patterns 
of the whole genome during the alteration of growth envi-
ronment, implying that they are less driven by selective 
pressures; and (2) these mutations do not significantly 
contribute to the attenuation of pathogenicity. The above 
results suggest that viral genome evolution is a compre-
hensive result of different gene changes and mutations 
during the process of vaccine development and that the 
env may play crucial roles in the attenuation of patho-
genicity [6]. The env is closely related to the virus’s target-
ing ability and immunogenicity. Multiple lines of evidence 
have demonstrated that the Env of highly virulent lenti-
viral strains contributes to stronger neutralization escape 
capabilities, enterotoxic activities and the ability to acti-
vate signaling pathways of inflammatory factors com-
pared to the Env of attenuated strains [7].
Table 1 Comparison of nucleotide and amino acid genetic distances of the various EIAVs compared to EIAVLN40 and EIA-
VDV117
a The number in parenthesis indicate standard deviation
b The gp45 amino acid genetic distances of EIAVFDDV13 with EIAVLN40 and EIAVDV117 no showed, because existence of truncated gp45
EIAVLN40 EIAVDV117
EIAVDV117 EIAVDLV34 EIAVDLV62 EIAVDLV92 EIAVDLV121 EIAVFDDV13 EIAVDLV34 EIAVDLV62 EIAVDLV92 EIAVDLV121 EIAVFDDV13
LTR nu 2.90 (0.85)a 3.30 (0.84) 4.18 (1.11) 4.18 (1.16) 4.06 (1.01) 5.86 (1.40) 1.94 (0.58) 2.97 (0.90) 3.68 (1.01) 2.59 (0.77) 3.71 (1.09)
Gag nu 2.02 (0.35) 1.72 (0.26) 1.96 (0.29) 2.16 (0.31) 2.30 (0.32) 2.47 (0.37) 2.13 (0.29) 2.31 (0.31) 2.58 (0.34) 2.62 (0.32) 2.57 (0.36)
aa 1.91 (0.51) 1.69 (0.42) 2.09 (0.53) 2.08 (0.53) 2.73 ± (0.58) 2.31 (0.57) 1.98 (0.45) 2.12 (0.50) 2.25 (0.53) 2.73 (0.54) 2.14 (0.50)
Pol nu 1.99 (0.24) 1.93 (0.16) 2.00 (0.10) 2.06 (0.19) 2.40 (0.20) 2.75 (0.23) 1.65 (0.16) 1.77 (0.16) 1.74 (0.17) 2.13 (0.19) 2.38 (0.23)
aa 2.03 (0.41) 2.13 (0.34) 2.27 (0.34) 2.38 (0.36) 2.49 (0.38) 2.84 (0.43) 1.35 (0.23) 1.69 (0.26) 1.61 (0.26) 1.79 (0.27) 2.00 (0.32)
gp90 nu 3.13 (0.43) 3.28 (0.39) 3.40 (0.41) 3.51 (0.41) 3.94 (0.44) 4.01 (0.48) 3.43 (0.40) 3.46 (0.42) 3.60 (0.43) 3.99 (0.43) 3.78 (0.46)
aa 4.20 (0.91) 5.17 (0.82) 5.17 (0.87) 5.55 (0.91) 6.07 (0.90) 6.71 (1.11) 6.38 (0.93) 6.20 (0.94) 6.38 (0.97) 7.05 (1.04) 7.59 (1.18)
gp45 nu 2.45 (0.38) 2.28 (0.29) 2.36 (0.26) 2.40 (0.29) 2.60 (0.31) 2.86 (0.41) 1.64 (0.23) 1.89 (0.23) 1.86 (0.27) 2.18 (0.29) 2.32 (0.40)
aa 3.31 (0.69) 3.14 (0.55) 3.56 (0.50) 3.22 (0.53) 3.42 (0.53) –b 1.78 (0.41) 2.60 (0.44) 2.14 (0.47) 2.71 (0.53) –
Tat nu 1.62 (0.73) 1.13 (0.36) 1.40 (0.45) 1.74 (0.57) 2.04 (0.67) 2.27 (0.79) 2.28 (0.72) 2.44 (0.75) 2.59 (0.78) 2.61 (0.80) 2.85 (0.90)
aa 2.05 (1.26) 2.26 (0.97) 2.93 (1.27) 3.76 (1.51) 4.38 (1.91) 5.11 (2.11) 2.98 (1.36) 3.29 (1.45) 3.81 (1.53) 3.19 (1.61) 3.93 (1.83)
S2 nu 1.97 (0.91) 1.72 (0.48) 2.14 (0.77) 2.45 (0.88) 2.94 (1.01) 2.45 (0.98) 3.00 (0.96) 3.31 (1.11) 3.12 (1.07) 4.10 (1.29) 2.85 (1.10)
aa 3.60 (2.20) 6.85 (2.51) 8.08 (3.23) 7.57 (2.99) 10.61 (3.81) 6.38 (3.10) 4.17 (1.36) 5.62 (2.47) 6.78 (2.75) 7.97 (3.09) 6.38 (3.13)
Rev nu 1.62 (0.50) 1.61 (0.37) 1.81 (0.33) 1.50 (0.34) 1.81 (0.35) 2.23 (0.65) 1.57 (0.39) 1.94 (0.39) 1.59 (0.39) 1.86 (0.38) 1.58 (0.54)
aa 2.52 (0.77) 3.29 (0.72) 2.48 (0.63) 3.64 (0.84) 5.70 (1.87) 3.47 (0.12) 4.25 (0.11) 3.66 (0.11) 4.45 (0.10) 4.77 (0.63) 2.52 (0.77)
Complete 2.29 (0.12) 2.22 (0.13) 2.37 (0.17) 2.56 (0.11) 2.78 (0.10) 3.15 (0.11) 2.10 (0.11) 2.25 (0.15) 2.38 (0.12) 2.57 (0.13) 2.81 (0.17)
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Stable mutation rates during the development of an EIAV 
attenuated vaccine
To elucidate the meaning of the EIAV genome evolu-
tion and the contributions of the mutations in each gene 
to the altered viral functions during long-term in  vivo 
and ex  vivo passaging, the mutational characteristics of 
the LTR and viral genes were extensively analyzed using 
the predominant sequence of EIAVLN40 as the reference 
(Figs. 3, 4 and Additional file 2: Figure S2, Table 2). Some 
sequences contained premature stop codons in the cod-
ing region; these genes might play some roles in the qua-
sispecies reservoir but were defective in the virus and 
were excluded from the analysis. For the convenience of 
description, we classified the seven viral strains accord-
ing to their pathogenicity and origins into the following 
groups: virulent strains (EIAVLN40, EIAVDV117, EIAVDLV34 
and EIAVDLV62); in  vivo highly virulent strains (EIA-
VLN40 and EIAVDV117); attenuated strains (EIAVDLV92, 
EIAVDLV121 and EIAVFDDV13); cell culture adapted viral 
strains (EIAVDLV34, EIAVDLV62, EIAVDLV92, EIAVDLV121 
and EIAVFDDV13); and vaccine strains (EIAVDLV121 and 
EIAVFDDV13). Some strains could be placed in more than 
one group because of different classification categories.
The LTR region contained the highest mutation rate 
in the genomic sequence because of insertions, dele-















































































































































































































Fig. 2 Phylogenetic tree analysis of EIAV proviral genomes and individual genes (gag, pol, env, tat, s2, rev and LTR). Sequence data were collected 
from 65 complete proviral genomes of seven viral strains. The phylogenetic trees were constructed using the neighbor‑joining method and 
calculated with the Kimura 2 parameter in MEGA 5. Bootstrap values above 70 % are indicated. The virulent strains, including EIAVLN40, EIAVDV117, 
EIAVDLV34 and EIAVDLV62, are viruses that cause typical EIA symptoms (rectal temperature >39 °C, the platelet count <100,000/μL and the plasma viral 
load >106 copies/mL)
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largely clustered in the U3 region, which consisted of 
the negative regulation element (NRE) and enhancer 
region (EHR). Most of the deletion and insertion muta-
tions were identified in this region and were presumed to 
result in changes in the number and specificity of binding 
sites for cellular transcription factors (Fig. 3). The E_box 
is the bHLH transcription factor binding sequence. It was 
originally absent in the two in  vivo virulent strains, but 
it appeared in the EHR in all of the cell culture adapted 
virus strains. The E_box sequence in the LTR of HIV-1 
and human T cell leukemia virus-1 (HTLV-1) was found 
to significantly decrease or delay the transcription of the 
provirus [8]. Additionally, sequences with AP-1 binding 
sites in the NRE region began to appear and gradually 
increased concomitantly with the successive passages in 
cultured cells. The clones of the most attenuated strain 
(EIAVFDDV13) contained two to three AP-1 binding sites. 
The transcription factor AP-1 is known to regulate cell 
differentiation, proliferation and apoptosis in multiple 
cell types. Studies of FIV revealed that the AP-1 binding 
sites in the U3 region improved viral replication in feline 
kidney cell lines but decreased viral propagation in feline 
T lymphocytes and PBMCs [9]. In this study, the repli-
cation ability in cultured cells of the EIAV strains was 
positively correlated with the AP-1 copy number and the 
percentage of clones with high-copy AP-1 but was nega-
tively correlated with viral pathogenicity. The fibroblast 
(FDD cells)-adapted EIAVFDDV13 lost the GATA binding 
site, which was present in the EHR region in the other 
strains. The transcription factor GATA regulates hemat-
opoietic differentiation and is necessary for the devel-
opment, differentiation and maturation of erythrocytes 
[10].
A predominant mutation in coding sequences is 
defined as that more than 10 % of clones in different viral 
strains exhibit mutations causing the change of same 
amino acid or more than 2/3 of clones in the same viral 
strain display the identical mutation sites. The EIAV 
Gag protein is a precursor that is subsequently hydro-
lyzed into the p15 matrix, p26 capsid, p11 nucleocapsid 
and p9 proteins. Four out of 14 predominant mutations 
were specifically generated during the period of ex  vivo 
attenuation (Additional file 2: Figure S2A). Among these 
four sites, 100A/T(S), 103T/S and 447N/D were mostly 
observed in the cell culture adapted viruses; the first two 
were located in the CTL epitope region in the E2 domain 
of p15 and the third was located in p9. In contrast, the 

































































































































Fig. 3 Alteration of the transcription factor binding motifs in the LTR U3 region. Sequences of 134 clones of the LTR from seven EIAV strains were 
randomly isolated from PCR‑amplified fragments and analyzed. NRE indicates the negative regulation element and EHR indicates the enhancer 
region. The boxes define transcription factor binding sites. The numbers at the left end of the gray lines indicate the detected clones of each strain. 
The numbers in parentheses refer to the numbers of clones that contain the indicated transcription factor binding site
Page 7 of 13Wang et al. Retrovirology  (2016) 13:9 
fully attenuated virus strains. The p9 protein is important 
for provirus formation and viral budding [11].
The cleavage of the EIAV Pol precursor protein gen-
erates several viral enzymes that are essential for the 
viral life cycle, including the reverse transcriptase (RT)/
RNaseH, a viral protease, a dUTPase and an integrase. 
During the EIAV vaccine development process, 24 pre-
dominant mutation sites were observed in Pol (Addi-
tional file  2: Figure S2B). Among these sites, three 
were primarily identified in the viral strains adapted 
in cultured cells (16 K/E, 27E/G and 598 K/R), with the 
first two located in the leader sequences. Additionally, 
another three mutations were primarily confined to the 
three attenuated strains (64G/E, 619  N/D and 820I/M), 
with two located in the RT/RNaseH region and one in 
the dUTPase region. The dUTPase plays important roles 
in influencing pathogenicity [12]. Indeed, Pol is closely 
associated with viral replication and the induction of 
immune responses. The outcomes of these viral strain-
associated mutations in EIAV Pol are less understood 
Fig. 4 The stable mutations of EIAV gp90. a Stable mutations in gp90 proteins generated during different vaccine development stages. The amino 
acid sequences were deduced from the gene sequences originating from either the proviral genomes or from the directly cloned PCR products 
after removing sequences containing premature stop codons. The gp90 sequences were aligned to the reference sequence EIAVLN40. The shadowed 
residues and white background residues are identical to or different from the reference sequence, respectively. Stable mutation sites detected 
primarily in virus strains adapted to cultivated cells are boxed, whereas those limited in the attenuated strains are marked with red circles. V1–V8 
designate the eight variable regions. The numbers on the top of the graphs show the positions of stable mutation sites, and those at the left side 
indicate the sequences applied for the analysis. The downward arrows indicate the direction of the vaccine development process. b The changes in 
gp90 glycosylation sites during vaccine development. The 116 gp90 sequences of seven different EIAV strains were analyzed using the N‑GlycoSite 
program (http://www.hiv.lanl.gov/content/sequence/GLYCOSITE/glycosite.html). The letter “n” in the labels on the right side indicates the total clone 
number. The numbers below show the average, minimum and maximum values of predicted N‑glycosylation sites. The Y-axis shows the percentage 
of each glycosylation site in the detected clones
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than the outcomes of mutations in other proteins such as 
Env and S2 [7, 13–15], and therefore they require further 
investigation.
The env gene was the structural gene with the highest 
mutation rate during vaccine development. Most of these 
mutations were located in the envelope surface unit gp90, 
which contained 43 predominant mutation sites (Fig. 4a). 
Impressively, nine of these mutations were confined to 
the cell culture adapted viral strains. Five were primar-
ily observed in the attenuated strains (180E/K in the V3 
region and 236D/-, 237N/K, 246N/K and 247E/K in the 
V4 region), including four that resulted in a change of an 
acidic amino acid to a basic amino acid. The deletion of 
negatively charged 236D in the V4 region may lead to a 
polarity change of the V4 region. Liang et al. previously 
demonstrated that the reverse mutation of these nine 
substituted residues in gp90 in the vaccine strain EIA-
VFDDV13 did significantly alter the pathogenicity of EIAV 
[16]. Heavy glycosylation is a common feature of lenti-
viral envelope proteins, and the locations and numbers 
of glycosylation sites are associated with viral biologi-
cal characteristics [17]. We found that the EIAV strains 
exhibited a decrease in gp90 glycosylation sites with the 
increasing passages in cultured cells. The average number 
Table 2 The proportion of stable amino acid substitutions of each gene in various EIAVs
EIAVLN40 EIAVDV117 EIAVDLV34 EIAVDLV62 EIAVDLV92 EIAVDLV121 EIAVFDDV13
Gag
100A/T(S) 0 (0/4) 0 (0/4) 43 (3/7) 100 (16/16) 100 (7/7) 100 (9/9) 100 (10/10)
103T/S 0 (0/4) 0 (0/4) 57 (4/7) 63 (10/16) 71 (5/7) 100 (9/9) 100 (10/10)
447N/D 0 (0/4) 0 (0/4) 33 (2/6) 63 (10/16) 33 (2/6) 67 (6/9) 90 (9/10)
484D/N 0 (0/4) 0 (0/4) 0 (0/6) 0 (0/16) 33 (2/6) 78 (7/9) 100 (10/10)
Pol
16K/E 0 (0/3) 0 (0/4) 50 (4/8) 92 (12/13) 100 (6/6) 100 (9/9) 100 (11/11)
27E/G 0 (0/3) 0 (0/4) 25 (2/8) 62 (8/13) 17 (1/6) 67 (6/9) 91 (10/11)
64G/E 0 (0/3) 0 (0/4) 0 (0/8) 0 (0/13) 50 (3/6) 67 (6/9) 100 (11/11)
598K/R 0 (0/3) 0 (0/4) 13 (1/8) 39 (5/13) 100 (6/6) 100 (9/9) 100 (11/11)
619N/D 0 (0/3) 0 (0/4) 13 (1/8) 0 (0/13) 50 (3/6) 67 (6/9) 55 (6/11)
820I/M 0 (0/3) 0 (0/4) 0 (0/8) 0 (0/13) 17 (1/6) 67 (6/9) 91 (10/11)
gp90
46A/E 0 (0/19) 0 (0/16) 87 (13/15) 100 (15/15) 100 (17/17) 100 (15/15) 100 (16/16)
98G/R 0 (0/19) 0 (0/16) 100 (15/15) 93 (14/15) 94 (16/17) 93 (14/15) 100 (16/16)
100K(H)/Q 0 (0/19) 0 (0/16) 100 (15/15) 100 (15/15) 100 (17/17) 100 (15/15) 100 (16/16)
103H/Y 0 (0/19) 0 (0/16) 93 (14/15) 100 (15/15) 94 (16/17) 87 (13/15) 100 (16/16)
180E/K 0 (0/19) 0 (0/16) 7 (1/15) 0 (0/15) 6 (1/17) 47 (7/15) 88 (14/16)
189K/E 0 (0/19) 0 (0/16) 80 (12/15) 100 (15/15) 94 (16/17) 93 (14/15) 100 (16/16)
190E/K 0 (0/19) 0 (0/16) 73 (11/15) 100 (15/15) 100 (17/17) 100 (15/15) 100 (16/16)
193S/N 0 (0/19) 6 (1/16) 100 (15/15) 100 (15/15) 100 (17/17) 100 (15/15) 100 (16/16)
236D/-(N) 0 (0/19) 0 (0/16) 13 (2/15) 47 (7/15) 82 (14/17) 100 (15/15) 100 (16/16)
237N/K 0 (0/19) 0 (0/16) 0 (0/15) 0 (0/15) 35 (6/17) 93 (14/15) 100 (16/16)
246N/K 0 (0/19) 0 (0/16) 13 (2/15) 20 (3/15) 29 (5/17) 60 (9/15) 94 (15/16)
247E/K 0 (0/19) 0 (0/16) 20 (3/15) 7 (1/15) 6 (1/17) 53 (8/15) 94 (15/16)
321K/E(N) 0 (1/19) 0 (0/16) 100 (15/15) 100 (15/15) 100 (17/17) 100 (15/15) 100 (16/16)
410H/Q 0 (0/19) 0 (0/16) 53 (8/15) 73 (11/15) 63 (10/16) 80 (12/15) 94 (15/16)
gp45 58V(I)/T 0 (0/5) 0 (0/5) 0 (0/7) 33 (5/15) 13 (1/8) 88 (7/8) 100 (7/7)
Tat 7R/H 0 (0/5) 0 (0/5) 44 (4/9) 67 (10/15) 100 (7/7) 100 (11/11) 100 (11/11)
S2
41T/I 0 (0/5) 0 (0/5) 56 (5/9) 73 (11/15) 75 (6/8) 100 (11/11) 100 (11/11)
51T/I 0 (0/5) 0 (0/5) 33 (3/9) 80 (12/15) 88 (7/8) 100 (11/11) 100 (11/11)
55Q/K 0 (0/5) 0 (0/5) 33 (3/9) 100 (15/15) 100 (8/8) 100 (11/11) 100 (11/11)
Rev 74V/I 0 (0/5) 0 (0/5) 0 (0/7) 13 (2/16) 38 (3/8) 70 (7/10) 100 (9/9)
0-30%˗ 31-70%˗ 71-100%
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of glycosylation sites in the virulent strains was 19–20 
compared to an average of 18 in the initially attenuated 
strain EIAVDLV92 and 17 for the vaccine strains EIA-
VDLV121 and EIAVFDDV13 (Fig. 4b).
The 237N/K and 246N/K substitutions in the gp90 of 
the attenuated strains resulted in the loss of two potential 
glycosylation sites (237NNTW240 and 246NETW249) 
in the V4 region (Fig.  4b). Additionally, all cell cul-
ture adapted viral strains lost the glycosylation site 
191NSSN194 in the V3 region because of the 193S/N 
substitution (Fig.  4b). Han et  al. reported that these 
substitutions reduced viral replication and sensitivity 
to neutralizing antibodies in cultured cells [18]. Howe 
et  al. demonstrated that the structure of the V4 region 
was important for EIAV evasion of immune surveillance, 
and the glycosylation sites in the V4 region blocked the 
principle neutralizing domain (PND) in the V3 region 
[19]. These structural features improved the resistance 
to host immune responses. The EIAV V3/V4 regions 
and the HIV-1 V1/V2 regions are topologically simi-
lar [20]. Recently, an analysis of the HIV-1 vaccine that 
was assessed in the Thailand RV-144 trial suggested that 
antibodies targeting the V1/V2 regions of gp120, which 
together form a five-strand beta barrel, were correlated 
with immune protection [21]. Therefore, the loss of glyco-
sylation sites in the V4 region in attenuated EIAV strains 
may cause viruses to expose more epitopes for immune 
recognition (particularly the PND in the V3 region), lead-
ing to stronger stimulation of immune responses.
Our sequencing data displayed that the diversity of 
gp90 a.a was the highest among other EIAV structural 
proteins, ranging from 1.85  ±  0.25  % for EIAVLN40 to 
4.14  ±  0.50  % for EIAVDV117, which implicated a wide 
variation in the surface antigens in different viral clones 
of EIAV quasispecies. Together with constant antigen 
shifting, the complexity in EIAV antigen composition 
results in the difficulty in vaccine development. We pre-
viously reported that a proviral derivate from the vaccine 
strain EIAVFDDV12 failed to elicit immune protection like 
its parental strain. The reduction of gp90 variation was 
considered the major difference between these two types 
of vaccine [4].
The EIAV trans membrane protein gp45 displayed 
a total of 10 predominant mutations, among which 
58V(I)/T was primarily detected in the vaccine strains 
(Additional file  2: Figure S2C). We previously dem-
onstrated that this mutation decreased the tempera-
ture sensitivity of gp45 [22], which might affect viral 
infection. Furthermore, all seven analyzed EIAVFDDV13 
genomes contained a G/A mutation at the 795th nucleo-
tide that created a premature stop codon (793TGA795) in 
the gp45 gene, resulting in a truncated gp45. The viruses 
expressing truncated gp45 grew significantly better in 
FDD cells than in horse macrophage. However, there was 
no significant difference in replication in horses between 
the two EIAV strains with different gp45 configurations 
[23]. The C-terminal truncated mutant may be positively 
selected because of its benefits for viral replication in 
FDD cells.
EIAV encodes three accessory proteins (Tat, S2 and 
Rev). Corresponding functional domains in Tat and the 
LTR bind to the TAR region of the EIAV genomic RNA 
to increase gene transcription efficiency. Our analysis 
revealed that Tat contained four predominant mutations, 
among which 7R/H was primarily found in the cell cul-
ture adapted viral strains (Additional file 2: Figure S2D). 
S2, which was the EIAV-encoded protein with the highest 
amino acid mutation rate in the vaccine strains compared 
to the initial EIAVLN40, contained six predominant muta-
tions. Of these, 6K/R was only observed in the highly vir-
ulent EIAVDV117 strain, whereas 41T/I, 51T/I and 55Q/K 
were mostly located in the cell culture adapted adapted 
strains (Additional file  2: Figure S2D). We previously 
demonstrated that the reverse mutation of these four 
substituted residues in the vaccine strain EIAVFDDV13 
compared to the residues from EIAVDV117 did not sig-
nificantly change the replication features of this vaccine 
strain in cultured cells [24]. Rev assists viral RNA trans-
portation out of the nucleus and is an important factor 
influencing lentivirus pathogenicity. Eleven predomi-
nant mutations were generated in Rev during the vaccine 
development process (Additional file  2: Figure S2D). 
Compared to the initial strain EIAVLN40, most clones of 
other strains displayed a deletion of residue N at posi-
tion 22. Two stable mutations were principally observed 
in EIAVDV117, and a third mutation (74V/I) was primarily 
detected in the vaccine strains.
In most cases, 33 of the aforementioned predominant 
mutations were stably maintained during the attenuating 
process in cultured cells, but were maintained in only a 
portion of the clones detected from related viral strains. 
The percentages generally increased as the passaging in 
cultured cells continued and were correlated with the 
decrease in pathogenicity (Fig. 3 and Table 2). This evi-
dence suggested the shifting of predominant clones in the 
pool of EIAV quasispecies. To evaluate the relationship 
between these stable mutations and the attenuation of 
pathogenicity and the alternation of the growth environ-
ment (from in vivo to ex vivo), a statistical analysis was 
performed to examine the differences between virulent 
and attenuated strains and between in  vivo-originated 
and cell culture adapted strains (Table 3). With the excep-
tion of 447N/D, all other stable mutations in Gag pre-
sented in Table 3 were significantly different between the 
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virulent and attenuated strains. Furthermore, all stable 
mutation sites summarized in Table 3 were significantly 
different between the in  vivo-originated strains and the 
cell culture adapted strains, with the exception of a few 
mutations including 484D/N in Gag, 16K/E, 598K/R and 
820I/M in Pol and 58V(I)/T in gp45. These data suggest 
that most of these stable mutations are responsible for 
EIAV adaptation to cultured cells and are correlated with 
changes in pathogenicity.
Conclusions
The vaccine development process of the attenuated EIAV 
vaccine is based on successive passages in different hosts 
and cultivated permissive cells to reduce pathogenicity 
while retaining immunogenicity. Viral strains collected at 
key stages of this process provided an important source 
of genomic information for studies on the molecular basis 
of the altered virological and immunological features. 
Our data demonstrated that different regions of the viral 
Table 3 Differences between  various amino acid sequences or LTR sequences derived from  virulent and  avirulent EIAV 
and in vivo and cell culture derived EIAV
a Virulent strains including EIAVLN40, EIAVDV117, EIAVDLV34, and EIAVDLV62
b Avirulent strains including EIAV DLV92, EIAVDLV121, and EIAVFDDV13
c In vivo strains including EIAVLN40 and EIAVDV117
d Ex vivo strains including EIAVDLV34, EIAVDLV62, EIAV DLV92, EIAVDLV121, and EIAVFDDV13
e Determined by the Chi square test of the SAS 9.2
Virulenta Avirulentb p Vivoc Vitrod pe
Gag 100A/T 19 (31) 25 (36) <0.01 0 (8) 45 (49) <0.01
103T/S 14 (31) 24 (26) <0.01 0 (8) 41 (49) <0.01
447N/D 12 (31) 16 (26) >0.05 0 (8) 28 (49) <0.01
484D/N 0 (31) 17 (26) <0.01 0 (8) 19 (49) >0.05
Pol 16K/E 16 (28) 26 (26) <0.01 0 (8) 19 (47) >0.05
27E/G 10 (28) 17 (26) 0.05 < p < 0.01 0 (7) 42 (47) <0.01
64G/E 0 (28) 20 (26) <0.01 0 (7) 27 (47) 0.05 < p < 0.01
598K/R 6 (28) 26 (26) <0.01 0 (7) 20 (47) >0.05
619N/D 1 (28) 15 (26) <0.01 0 (7) 23 (47) 0.05 < p < 0.01
820I/M 0 (28) 17 (26) <0.01 0 (7) 16 (47) >0.05
gp90 46A/E 28 (65) 48 (48) <0.01 0 (35) 76 (78) <0.01
98G/R 29 (65) 45 (48) <0.01 0 (35) 75 (78) <0.01
100K/(H)Q 46 (65) 48 (48) <0.01 16 (35) 78 (78) <0.01
103H/Y 30 (65) 45 (48) <0.01 0 (35) 75 (78) <0.01
180E/K 1 (65) 22 (48) <0.01 1 (35) 22 (78) <0.01
189K/E 27 (65) 46 (48) <0.01 0 (35) 73 (78) <0.01
190E/K 27 (65) 48 (48) <0.01 0 (35) 74 (78) <0.01
193S/N 31 (65) 48 (48) <0.01 1 (35) 78 (78) <0.01
236D/‑(N) 9 (65) 45 (48) <0.01 0 (35) 54 (78) <0.01
237N/K 0 (65) 36 (48) <0.01 0 (35) 67 (78) <0.01
246N/K 5 (65) 29 (48) <0.01 0 (35) 33 (78) <0.01
247E/K 4 (65) 24 (48) <0.01 0 (35) 28 (78) <0.01
321K/E(N) 31 (65) 48 (48) <0.01 1 (35) 78 (78) <0.01
410H/Q 19 (65) 37 (48) <0.01 0 (35) 56 (78) <0.01
gp45 58V(I)/T 5 (32) 15 (23) <0.01 0 (10) 26 (45) >0.05
Tat 7R/H 14 (34) 29 (29) <0.01 0 (10) 43 (53) <0.01
S2 41T/I 16 (34) 28 (30) <0.01 0 (10) 44 (54) <0.01
51T/I 15 (34) 28 (30) <0.01 0 (10) 41 (54) <0.01
55Q/K 18 (34) 30 (30) <0.01 0 (10) 46 (54) <0.01
Rev 74V/I 2 (35) 19 (27) <0.01 0 (10) 21 (52) <0.01
LTR AP‑1 4 (77) 57 (65) <0.01 0 (38) 61 (104) <0.01
MDBP 14 (77) 33 (65) <0.01 1 (38) 46 (104) <0.01
E_box 30 (77) 56 (65) <0.01 0 (38) 86 (104) <0.01
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genome that are associated with decreased pathogenicity 
exhibited a series of stable mutations and that the per-
centage of mutated sites in the viral population gradually 
increased. These results indicated that these mutations 
were closely involved in pathogenicity attenuation and 
immunogenicity enhancement. The evolutionary analysis 
revealed that although the direction of evolution of the 
whole genome was consistent with the extent of attenu-
ation, not all of the individual genes followed the same 
evolutionary pattern. This finding implicates the differ-
ent contributions of each gene to the adaption of EIAV to 
changes in the growth environment and attenuation. Fur-
thermore, our results suggest that there is a cumulative 
effect of the mutations in each individual gene on phe-
notypic alterations, including pathogenicity and immu-
nogenicity. The stable mutation data presented in this 
article provide genetic information for future studies to 
determine the factors involved in viral infectivity.
Methods
Viruses and cells
EIAV strains were stocked in the Harbin Veterinary 
Research Institute, Chinese Academy of Agricultural Sci-
ences. EIAVLN40 and EIAVDV117 were originally obtained 
from peripheral blood mononuclear cells (PBMCs) col-
lected during febrile episodes from horses or donkeys 
infected with EIAVLN40 or EIAVDV117, respectively. The 
strains were stored at −80 °C prior to analysis. EIAVDLV34, 
EIAVDLV62, EIAVDLV92, EIAVDLV121 and EIAVFDDV13 were 
obtained as lyophilized cell culture supernatants and 
reconstituted in sterile cattle serum. EIAVDLV34, EIA-
VDLV62, EIAVDLV92 and EIAVDLV121 were rejuvenated in 
dMDM, and the cells were harvested when they showed 
cytopathic effects. EIAVFDDV13 was rejuvenated in FDD, 
and the cells were harvested 10  days after inoculation. 
Dynamic replication curves were performed for sev-
eral passages of EIAV strains, including EIAVDLV34, EIA-
VDLV62, EIAVDLV92, EIAVDLV121 and EIAVFDDV13. The 
same copy number of EIAVDLV34, EIAVDLV62, EIAVDLV92, 
EIAVDLV121 and EIAVFDDV13 was used to infect cultured 
dMDM, which was determined by quantitative real-time 
revers transcription (RT)-PCR of the gag gene fragment 
[4, 6]. The supernatants were collected from the infected 
cells at 2, 4, 6, 8 and 10  days post-infection to measure 
the viral quantity by assessing the reverse transcriptase 
(RT) activity (Additional file 2: Figure S1) [21].
Amplification and sequencing
The proviral DNA of EIAVLN40 and EIAVDV117 were pre-
pared from peripheral blood mononuclear cells (PBMC) 
taken during febrile episodes of horses or donkeys infected 
by EIAVLN40 or EIAVDV117, respectively. Proviral DNA of 
EIAVDLV34, EIAVDLV62, EIAVDLV92 and EIAVDLV121 were 
obtained from cultured dMDM, EIAVFDDV13 proviral DNA 
was from FDD cells, infected by respective EIAV strains. 
Total cellular DNA was extracted using the OMEGA 
Blood DNA Kit (OMEGA, Shanghai, China) according to 
the manufacturer’s protocols. Proviral genomes of EIA-
VLN40, EIAVDV117, EIAVDLV121 and EIAVFDDV13 were cloned 
and sequenced from two amplified fragments using long 
and accurate PCR (LA-PCR) [25, 26]. The near entire pro-
viral genome (7.9  kb of 8.2  kb) of EIAVDLV34, EIAVDLV62 
and EIAVDLV92 proviral genomes were amplified by LA-
PCR. To analyze the evolutionary characteristics of the 
long terminal repeat (LTR) region and the gp90 gene in 
detail, specific gene fragments were also directly amplified 
from proviral DNA of individual virus strains and cloned 
individually in addition to the whole genomes. After T-A 
cloning of PCR products, positive clones were sent for 
sequencing to obtain 5–16 whole-genome sequences, 
19–23 LTR sequences and 16–21 gp90 sequences from 
different viral strains. All clones were obtained from indi-
cated viral genomic fragments amplified by three to five 
independent PCR reactions.
Sequence and phylogenetic analysis
Nucleotide sequences were edited and assembled using 
the SeqManII tool of the Lasergene DNAStar program 
7.1 (DNAStar) (Madison, WI, USA, 2006). The Mega-
lign tool (DNAStar) was used for pairwise and multiple 
alignments of DNA sequences and for deducing amino 
acid sequences. Shannon entropy was calculated using 
BioEdit software [27]. Diversity and distance were calcu-
lated using the Molecular Evolutionary Genetics Analy-
sis (MEGA) program 5 and a pairwise deletion option. 
Phylogenetic and molecular evolutionary analyses 
were conducted using MEGA5 (Center for Evolution-
ary Functional Genomics Biodesign Institute, Arizona 
State University, Tempe, AZ, USA, 2011) by the neighbor 
joining method [28]. Bootstrap values (based on 1000 
replicates) for each node were provided if they were at 
least 70  %. N-glycosylation sites were predicted using 
N-GlycoSite (http://www.hiv.lanl.gov/content/sequence/
GLYCOSITE/glycosite.html). The stable mutation rates 
(marginal frequencies at each position of the amino acid 
sequence) were calculated using the MargFreq software 
(http://sray.med.som.jhmi.edu/SCRoftware/MargFreq/). 
The statistical analysis of the sequence variations was 
performed using SAS (Statistical Analysis System) (ver-
sion 9.2, SAS Institute Inc, SAS Campus Drive, Cary, NC, 
USA, 2008).
Nucleotide sequence accession numbers
Sequences generated in this study have been submitted 
to GenBank (accession numbers: AF327878, AF327878, 
HM141919, GU385362–GU385365, GU385353–GU385362, 
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HM141909–HM141912, HM1419113–HM141918, HM1419120– 
HM1419123, KT806081–KT806112).
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